```html

Steroid‑Induced Diabetes

Overview

Steroid‑induced diabetes (SID), also called glucocorticoid‑induced hyperglycemia, is a form of secondary diabetes that develops after exposure to high‑dose or prolonged systemic glucocorticoid (steroid) therapy. Glucocorticoids such as prednisone, prednisolone, methylprednisolone, dexamethasone, and hydrocortisone are frequently prescribed for autoimmune disorders, asthma, inflammatory bowel disease, organ transplantation, and certain cancers. While these drugs are lifesaving, they can impair glucose metabolism and raise blood‑sugar levels enough to meet the diagnostic criteria for diabetes.

Who is affected? Anyone receiving systemic steroids is at risk, but certain groups are more vulnerable:

• Older adults (≥65 years)
• Individuals with pre‑existing impaired glucose tolerance or type 2 diabetes
• Those with obesity (BMI ≥ 30 kg/m²)
• Patients with a family history of diabetes
• People of Hispanic, African‑American, or South‑Asian descent (higher baseline diabetes risk)

Prevalence – Large cohort studies estimate that 10‑30 % of patients receiving high‑dose glucocorticoids develop new‑onset diabetes, and up to 50 % of those with pre‑existing glucose intolerance will see a worsening of glycemic control [Mayo Clinic 2023; CDC 2022]. In oncology, where steroid pulses are common, the incidence may exceed 35 %, especially when combined with other diabetogenic agents such as tyrosine‑kinase inhibitors.

Symptoms

Symptoms of steroid‑induced diabetes are indistinguishable from those of other forms of diabetes. Because glucocorticoids can raise blood glucose more rapidly than lifestyle factors alone, symptoms may appear within days to weeks after starting therapy.

• Polyuria (frequent urination): Excess glucose pulls water into the urine, causing increased volume.
• Polydipsia (excess thirst): Dehydration from polyuria triggers a compensatory thirst response.
• Polyphagia (increased hunger): Cells cannot use glucose efficiently, so the body signals for more fuel.
• Unexplained weight loss: Despite eating more, the body may break down fat and muscle for energy.
• Fatigue and weakness: Impaired glucose utilization leads to low energy.
• Blurred vision: High blood sugar draws fluid into the lens, affecting focus.
• Recurrent infections: Elevated glucose can impair immune function, leading to more frequent skin, urinary, or respiratory infections.
• Slow wound healing: Hyperglycemia interferes with collagen synthesis and leukocyte activity.

Because steroids also cause fluid retention and weight gain, patients may sometimes attribute these symptoms to the medication itself rather than to rising blood glucose, underscoring the need for regular monitoring.

Causes and Risk Factors

How steroids raise blood glucose

1. Increased hepatic gluconeogenesis: Glucocorticoids stimulate the liver to produce more glucose from amino acids and glycerol.
2. Reduced peripheral glucose uptake: They antagonize insulin signaling in muscle and adipose tissue, decreasing GLUT‑4 transporter translocation.
3. Enhanced insulin resistance: Chronic exposure alters adipokine profiles (↑ TNF‑α, ↓ adiponectin), fostering a resistant state.
4. Beta‑cell dysfunction: High steroid levels can impair pancreatic β‑cell insulin secretion, especially when combined with existing β‑cell stress.

Key risk factors

• Dosage & duration: Doses equivalent to ≥ 20 mg prednisone daily for > 2 weeks markedly raise risk.
• Route of administration: Oral and intravenous systemic steroids carry higher risk than inhaled, topical, or intra‑articular formulations (though high‑dose inhaled steroids can still affect glucose).
• Concurrent diabetogenic meds: Calcineurin inhibitors (cyclosporine, tacrolimus), antipsychotics, or protease inhibitors amplify hyperglycemia.
• Metabolic background: Obesity, metabolic syndrome, polycystic ovary syndrome (PCOS), and gestational diabetes history.

Diagnosis

Diagnosis follows the same criteria used for type 2 diabetes, but the temporal relationship to steroid exposure is essential.

Laboratory tests

• Fasting plasma glucose (FPG): ≥ 126 mg/dL (7.0 mmol/L) on two separate occasions.
• 2‑hour oral glucose tolerance test (OGTT): ≥ 200 mg/dL (11.1 mmol/L) after a 75 g glucose load.
• HbA1c: ≥ 6.5 % (48 mmol/mol). Note: Steroid‑induced hyperglycemia may appear before HbA1c rises, so FPG or OGTT can be more sensitive early on.
• Random plasma glucose: ≥ 200 mg/dL with classic symptoms.

Screening recommendations

Guidelines from the American Diabetes Association (ADA) and Endocrine Society suggest:

• Baseline FPG or HbA1c before initiating systemic steroids.
• Repeat fasting glucose 1–2 weeks after starting high‑dose therapy, then monthly if doses remain ≥ 20 mg prednisone equivalent.
• If steroids are tapered off, continue monitoring for 4–6 weeks, as hyperglycemia can persist.

Treatment Options

Treatment aims to control glucose while allowing patients to receive the necessary steroid regimen.

1. Lifestyle modifications

• Medical nutrition therapy: Focus on low‑glycemic‑index carbs, adequate fiber, and consistent carbohydrate counting. A dietitian can tailor a plan to steroid‑related appetite changes.
• Physical activity: 150 min/week of moderate‑intensity aerobic exercise improves insulin sensitivity. Even short, frequent walks can counteract steroid‑induced insulin resistance.
• Weight management: For overweight patients, a 5‑10 % weight loss can significantly lower glucose levels.

2. Pharmacologic therapy

Choice of medication depends on the severity of hyperglycemia, renal function, and the expected duration of steroid use.

Medication class	Typical use in SID	Key considerations
Short‑acting insulin (e.g., rapid‑acting analogs)	Preferred for fasting or post‑prandial spikes, especially when steroids are given in the morning.	Adjust dose based on glucose trend; safe in renal impairment.
Intermediate‑acting insulin (NPH)	Matches the pharmacokinetics of many oral steroids (peak glucose rise 4‑8 h after dose).	Risk of hypoglycemia if steroids are tapered quickly.
Basal‑bolus insulin regimen	For patients with persistent hyperglycemia despite steroids taper.	Requires education for dose titration.
Metformin	First‑line oral agent when renal function permits (eGFR ≥ 45 mL/min/1.73 m²).	Can be combined with insulin; gastrointestinal side effects.
GLP‑1 receptor agonists (e.g., liraglutide)	Useful for overweight patients; modest weight loss benefit.	Injectable; contraindicated in history of medullary thyroid carcinoma.
SGLT2 inhibitors (e.g., empagliflozin)	May be added in stable patients—provides cardiovascular/renal protection.	Risk of euglycemic ketoacidosis, especially with high-dose steroids; avoid in dehydration.

3. Adjusting steroid therapy

• Use the lowest effective dose and shortest duration possible.
• Consider alternate‑day dosing or switching to a less diabetogenic glucocorticoid (e.g., budesonide for certain GI conditions).
• Coordinate with the prescribing specialist (rheumatologist, oncologist, pulmonologist) to balance disease control and metabolic risk.

Living with Steroid‑Induced Diabetes

Daily monitoring

• Blood glucose checks: For patients on insulin, test fasting, pre‑meal, and 2‑hour post‑prandial levels (or as directed). Those on oral agents should at least check fasting glucose twice weekly.
• Logs: Keep a notebook or app record linking glucose readings to steroid dose timing, meals, and activity.

Practical tips

• Set medication alarms to avoid missed doses.
• Stay hydrated; glucocorticoids can cause fluid retention, but excess glucose pulls water from cells.
• Manage appetite: Steroids often increase hunger. Opt for high‑fiber, protein‑rich snacks (Greek yogurt, nuts).
• Watch for signs of infection early—skin, urinary, or respiratory—since hyperglycemia impairs immunity.
• Regular foot examinations if peripheral neuropathy or vascular disease is present.

When to contact your healthcare team

• Consistently fasting glucose > 130 mg/dL or post‑prandial > 180 mg/dL despite therapy.
• Episodes of hypoglycemia (≤ 70 mg/dL) after steroid taper.
• New or worsening infections, unexplained weight loss, or persistent fatigue.

Prevention

Prevention focuses on risk stratification before steroids are prescribed and proactive monitoring.

• Pre‑treatment screening: Obtain baseline fasting glucose or HbA1c. Identify high‑risk individuals.
• Choosing steroid type/dose: Prefer inhaled, topical, or budesonide formulations when clinically appropriate.
• Prophylactic metformin: Some specialists start metformin in high‑risk patients before initiating > 20 mg/day prednisone, though evidence is still emerging.
• Patient education: Discuss likely glycemic changes, how to test glucose, and when to seek help.
• Vaccinations: Ensure influenza, pneumococcal, and COVID‑19 vaccines are up to date to reduce infection‑related hyperglycemia.

Complications

If left uncontrolled, steroid‑induced diabetes carries the same long‑term complications as type 2 diabetes.

• Microvascular: Diabetic retinopathy, nephropathy, and peripheral neuropathy.
• Macrovascular: Accelerated atherosclerosis leading to myocardial infarction or stroke.
• Infections: Higher risk of cellulitis, urinary tract infections, and opportunistic fungal infections.
• Diabetic ketoacidosis (DKA): Rare but possible, especially if insulin is omitted during high‑dose steroid pulses.
• Osteoporosis: Combined effect of steroids and hyperglycemia worsens bone loss.

These complications underscore why regular follow‑up with primary care or endocrinology is critical.

When to Seek Emergency Care

References

1. Mayo Clinic. “Glucocorticoid‑induced diabetes.” Updated 2023. https://www.mayoclinic.org
2. American Diabetes Association. “Standards of Medical Care in Diabetes—2024.” Diabetes Care. 2024;47(Suppl 1):S1‑S350.
3. Endocrine Society Clinical Practice Guideline. “Management of Hyperglycemia in Patients Receiving Glucocorticoids.” 2022.
4. Centers for Disease Control and Prevention. “Steroid Use and Diabetes Risk.” 2022. https://www.cdc.gov
5. World Health Organization. “Global report on diabetes.” 2021.
6. Johns Hopkins Medicine. “Glucocorticoid‑Induced Hyperglycemia.” 2023.

```